Professor David Sinclair
Harvard University, MA
A recently named member of the TIME 100 "most influential people list", Professor Sinclair is widely known as one of the pioneers of ageing research. From a scientific perspective he maintains labs at Harvard Medical School as co-director of the Paul F Glenn Laboratories, and at UNSW, Australia. His research focuses on mechanisms of cell survival during old age and stress, such as that encountered during surgical interventions.
Professor Sinclair is also a renowned biotech entrepreneur, having founded or co-founded a number of influential companies including Sirtris (acquired by GlaxoSmithKline for $720M), Genocea Biosciences and Ovascience.
Chief Investment Officer, Deltec International Group
Atul is the Chief Investment Officer of Deltec International Group, responsible for the overall investment strategy and analytical process; and with his team, responsible for the overall Asset Allocation, Country Allocation; Sector Allocation and Stock Selection across Deltec’s managed portfolios and funds. Atul also manages the overall investment platform, which includes investment management, investment advisory, brokerage, investment funds, merchant banking and direct investments.
Prior to joining Deltec, Atul was the Head of Strategy & Economics for Credit Suisse, within Institutional Equities, based in Australia, and was top ranked by Clients and rated #1 in the Institutional Investor and Peter Lee / Greenwich Surveys over multiple years. Prior to Credit Suisse, Atul was a Partner and Portfolio Manager at White Funds Management, managing over $1bn Institutional and Retail funds across Equities, Fixed Income, Cash and Liquid Securities, Listed Real Estate and Alternatives, including experience in duration and cash flow matching for insurance and pension funds.
A respected authority on global macroeconomic issues and highly regarded across the industry, Atul is regularly requested to appear in the financial press, including Bloomberg, CNBC, The Wall Street Journal, The New York Times, The Financial Times and numerous other international publications, and has also been featured in a number of investment related books, including “Young Guns on the Share Market” and “Bulls, Bears and a Croupier”.
Executive Director, Macquarie Bank Limited
Andrew has spent more than 25 years in the financial services industry and has substantial experience in originating significant transactions and growing businesses both domestically and internationally including substantial M&A activity.
Andrew leads the Technology, Media, Telecoms (TMT) division within the Corporate and Asset Finance Group of Macquarie. The TMT division provides specialised financial and asset management solutions to major customers around the world. In addition to leading the TMT team Andrew has developed and closed a number of unique and significant transactions that have led to substantial benefits for Macquarie's customers.
Scientific Advisory Board
Dr Raj Reddy
Prince of Wales Hospital, Sydney, Australia
Dr Reddy is the head of Neurosurgery at Prince of Wales Hospital and a paediatric neurosurgeon at Sydney Children’s Hospital. Dr Reddy has a special interests in paediatric neurosurgery and spine surgery and has completed subspecialist training in complex spine surgery at Toronto Western Hospital and paediatric neurosurgery at The Hospital for Sick Children in Toronto.
Dr Reddy is a professional member of Neurosurgical Society of Australasia, Spine Society of Australasia, American Association of Neurological Surgeons, North American Spine Society, and International Society of Paediatric Neurosurgeons and is passionate about providing high quality evidenced base care and training the next generation of surgeons.
Professor David Morris
Professor Morris is Professor of Surgery at St George Hospital, Sydney. He is recognised as a world leader in surgical oncology and peritoneal cancer, having pioneered new treatments for cancer and associated conditions. He has published more than 800 peer reviewed articles, has maintained a science and oncology lab for more than 20 years and has an extensive track record of commercialising pharma and medical devices including through trade sale, licensing and IPO.